GlassHouse Research identified accounting red flags at Catalent. Fiat Lux Partners countered most of GlassHouse's claims. Who was right? This update explores the aftermath of the short seller duel.

Fund manager Janet Curie asked for a recommendation about the pharmaceutical company Catalent. The company seemed like a solid investment. However, a pair of research reports issued over the previous two months complicated this narrative. GlassHouse Research, a short seller that profited when stocks declined in value, identified accounting red flags at Catalent. Fiat Lux Partners, on the other hand, released a report countering most of GlassHouse's claims, arguing that GlassHouse fed investors red herrings. Both GlassHouse and Fiat Lux had anonymous funders and employees-and long disclaimers explaining their financial interests. Curie was at a loss-who, if anyone, could she trust? Who had uncovered actual wrongdoing, and who was using accounting tricks to mask or exaggerate real-world factors?